Zhejiang Hisun Animal Health Products Co., Ltd. (“Hisun Animal Health”), a controlling subsidiary of Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267), announced that it has received a Veterinary Drug Product Approval Number from the Ministry of Agriculture and Rural Affairs of the People’s Republic of China (MARA) for its Telmisartan Oral Solution (for cats), a veterinary pharmaceutical product indicated for the treatment of proteinuria caused by chronic kidney disease (CKD) in cats.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | Ministry of Agriculture and Rural Affairs (MARA), China |
| Approval Type | Veterinary Drug Product Approval Number |
| Product | Telmisartan Oral Solution (for cats) |
| Indication | Treatment of proteinuria caused by chronic kidney disease in cats |
| Approval Number | 兽药字 110803434 |
| Validity Period | 08 Oct 2026 – 07 Oct 2031 |
| Dosage Form | Oral solution |
| Specification | 30 ml : 0.12 g (calculated as C₃₃H₃₀N₄O₂) per container |
| Application Submitted | 30 Dec 2025 |
| Manufacturer | Zhejiang Hisun Animal Health Products Co., Ltd. |
| Production Site | No. 208 Golf Road, Dongzhou Street, Fuyang District, Hangzhou, Zhejiang Province |
Drug Profile & Mechanism of Action
- Molecule: Telmisartan — a selective angiotensin II type 1 (AT₁) receptor blocker (ARB) widely used in human medicine for hypertension and renoprotection, now formulated as a veterinary oral solution specifically dosed for feline patients.
- Mechanism in Feline CKD: Telmisartan selectively blocks the AT₁ receptor, reducing intraglomerular pressure and thereby decreasing proteinuria — a key biomarker and driver of disease progression in chronic kidney disease. By attenuating glomerular hyperfiltration, telmisartan helps slow the decline of renal function in affected cats.
- Formulation: Oral solution format designed for ease of administration in cats, addressing the practical challenges of pill‑based dosing in feline patients and improving owner compliance with long‑term treatment regimens.
- Therapeutic Significance: Chronic kidney disease is one of the leading causes of morbidity and mortality in geriatric cats, with proteinuria serving as both a prognostic indicator and a therapeutic target. Approved pharmacological options specifically indicated for feline CKD‑associated proteinuria remain limited in the Chinese veterinary market.
Competitive Landscape
- Key Competitors: Other approved manufacturers of telmisartan‑containing veterinary products in China include Luoyang Huizhong Veterinary Drug Co., Ltd. and Jiangsu Langbote Animal Pharmaceutical Co., Ltd.
- Market Data: As of the announcement date, Hisun Pharmaceutical has not been able to obtain specific sales revenue data for competing telmisartan veterinary products through publicly available channels.
- Market Entry Timing: Hisun Animal Health enters a growing but increasingly competitive feline CKD pharmaceutical segment, where timing of market launch, veterinary channel coverage, and brand recognition will be key differentiators.
Market Impact & Outlook
- Pet Pharmaceutical Growth in China: China’s companion animal pharmaceutical market has experienced rapid expansion driven by rising pet ownership, increasing veterinary spending, and growing awareness of chronic disease management in pets. Feline CKD therapeutics represent a high‑value, recurring‑revenue segment given the chronic nature of the condition and the need for long‑term treatment.
- Hisun Pharmaceutical Strategic Positioning: The approval strengthens Hisun’s pet pharmaceutical business segment, diversifying the company’s revenue base beyond its core human pharmaceutical operations and reinforcing its strategic commitment to the animal health vertical.
- Product Portfolio Enrichment: Telmisartan oral solution adds a clinically differentiated product to Hisun Animal Health’s portfolio, complementing existing offerings and enhancing the company’s competitive positioning in the veterinary cardiovascular and renal therapeutic areas.
- Commercial Execution Risk: The product now meets all regulatory requirements for commercial launch. However, actual sales performance will be influenced by national policy dynamics, veterinary formulary adoption, provincial procurement processes, competitive pricing pressure, and the pace of veterinary clinic penetration and brand building in the feline CKD segment.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization prospects of Hisun Animal Health’s telmisartan oral solution for cats, the growth of China’s pet pharmaceutical market, and the strategic positioning of Zhejiang Hisun Pharmaceutical in the animal health sector. Actual results may differ due to risks including market competition, regulatory policy changes, veterinary adoption rates, competitive product launches, and general economic conditions affecting pet owner spending.-Fineline Info & Tech
